EP1423693A4 - Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs - Google Patents
Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeursInfo
- Publication number
- EP1423693A4 EP1423693A4 EP01959479A EP01959479A EP1423693A4 EP 1423693 A4 EP1423693 A4 EP 1423693A4 EP 01959479 A EP01959479 A EP 01959479A EP 01959479 A EP01959479 A EP 01959479A EP 1423693 A4 EP1423693 A4 EP 1423693A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- erythropoietin
- combination therapy
- necrosis factor
- tumor necrosis
- factor alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/024384 WO2003012432A1 (fr) | 2001-08-02 | 2001-08-02 | Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1423693A1 EP1423693A1 (fr) | 2004-06-02 |
EP1423693A4 true EP1423693A4 (fr) | 2006-06-07 |
Family
ID=21742749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01959479A Withdrawn EP1423693A4 (fr) | 2001-08-02 | 2001-08-02 | Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1423693A4 (fr) |
JP (1) | JP2004537569A (fr) |
CA (1) | CA2456177A1 (fr) |
WO (1) | WO2003012432A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005055929A2 (fr) * | 2003-12-02 | 2005-06-23 | Celgene Corporation | Procedes et compositions de traitement et de gestion de l'hemoglobinopathie et de l'anemie |
WO2007139150A1 (fr) * | 2006-05-30 | 2007-12-06 | The University Of Tokushima | AGENT ANTI-VIRUS DE LA GRIPPE COMPRENANT L'INHIBITEUR DU TNF-α |
GR1005808B (el) * | 2006-11-27 | 2008-02-06 | Bionature E.A. Limited | Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010743A1 (fr) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Chimiotherapie antivirale et anticancereuse amelioree faisant appel a l'administration d'erythropoietine (epo) |
WO2002036152A1 (fr) * | 2000-10-31 | 2002-05-10 | Amgen Inc. | Utilisation d'inhibiteurs il-1 et d'antagonistes tnf, en partie en combinaison avec des erythropoietines de recombinaison, pour traiter l'anemie |
-
2001
- 2001-08-02 WO PCT/US2001/024384 patent/WO2003012432A1/fr active Application Filing
- 2001-08-02 JP JP2003517575A patent/JP2004537569A/ja active Pending
- 2001-08-02 CA CA002456177A patent/CA2456177A1/fr not_active Abandoned
- 2001-08-02 EP EP01959479A patent/EP1423693A4/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002010743A1 (fr) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Chimiotherapie antivirale et anticancereuse amelioree faisant appel a l'administration d'erythropoietine (epo) |
WO2002036152A1 (fr) * | 2000-10-31 | 2002-05-10 | Amgen Inc. | Utilisation d'inhibiteurs il-1 et d'antagonistes tnf, en partie en combinaison avec des erythropoietines de recombinaison, pour traiter l'anemie |
Non-Patent Citations (3)
Title |
---|
DEMETRI G D ET AL: "QUALITY-OF-LIFE BENEFIT IN CHEMOTHERAPY PATIENTS TREATED WITH EPOETIN ALFA IS INDEPENDENT OF DISEASE RESPONSE OR TUMOR TYPE: RESULTS FROM A PROSPECTIVE COMMUNITY ONCOLOGY STUDY", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 16, no. 10, October 1998 (1998-10-01), pages 3412 - 3425, XP009031711, ISSN: 0732-183X * |
See also references of WO03012432A1 * |
WOLCHOK J D ET AL: "PROPHYLACTIC RECOMBINANT EPOETIN ALFA MARKEDLY REDUCES THE NEED FOR BLOOD TRANSFUSION IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH BIOCHEMOTHERAPY", CYTOKINES, CELLULAR AND MOLECULAR THERAPY, MARTIN DUNITZ PUBLISHERS, LONDON, GB, vol. 5, no. 4, December 1999 (1999-12-01), pages 205 - 206, XP009031732, ISSN: 1368-4736 * |
Also Published As
Publication number | Publication date |
---|---|
EP1423693A1 (fr) | 2004-06-02 |
JP2004537569A (ja) | 2004-12-16 |
CA2456177A1 (fr) | 2003-02-13 |
WO2003012432A1 (fr) | 2003-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1463438A4 (fr) | Therapie endomurale | |
EG24356A (en) | Antitumor compounds and methods | |
AU2002352903A8 (en) | Mesoporous materials and methods | |
AU2003215460A8 (en) | Cancer associated protein kinases and their uses | |
GB0126879D0 (en) | Combination therapy | |
EP1368051A4 (fr) | Urocortine iii et certaines de ses utilisations | |
EP1401494A4 (fr) | Traitement anti-tumoral | |
GB0101933D0 (en) | Therapy | |
GB0108485D0 (en) | Combination therapy | |
GB0119025D0 (en) | Compounds and their therapeutic use | |
AU2002335667A1 (en) | Modified reoviral therapy | |
EP1423693A4 (fr) | Erythropoietine et traitement de combinaison alpha anti-facteur de necrose des tumeurs | |
GB0115780D0 (en) | Therapeutic molecules and uses thereof | |
HUP0401162A3 (en) | Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives | |
AU2001281032A1 (en) | Erythropoietin and anti-tumor necrosis factor alpha combination therapy | |
HU0200253D0 (en) | Combination therapy | |
EP1367333A4 (fr) | Pompe a chaleur et deshumidificateur | |
AU2002366364A8 (en) | E2f and cancer therapy | |
EP1463511A4 (fr) | Therapie anticancereuse combinatoire | |
GB2376943B (en) | Compounds and their therapeutic use | |
GB0112237D0 (en) | Compounds and their therapeutic use | |
AU2002348162A1 (en) | Antiviral combination therapy and compositions | |
GB0111494D0 (en) | Methods and therapeutic systems | |
AU2002321141A1 (en) | Pyrimidinoxyalkylpiperazines and their therapeutic use | |
AU2001279173A1 (en) | Cytokine modulation therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040301 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060504 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20060427BHEP Ipc: A61K 31/454 20060101ALI20060427BHEP Ipc: A61K 31/52 20060101ALI20060427BHEP Ipc: A61K 31/70 20060101ALI20060427BHEP Ipc: A01N 43/04 20060101ALI20060427BHEP Ipc: A01K 67/027 20060101ALI20060427BHEP Ipc: A01K 67/033 20060101ALI20060427BHEP Ipc: A01K 67/00 20060101ALI20060427BHEP Ipc: G01N 33/00 20060101ALI20060427BHEP Ipc: A61K 39/395 20060101ALI20060427BHEP Ipc: A61K 38/17 20060101ALI20060427BHEP Ipc: A61K 38/18 20060101AFI20060427BHEP |
|
17Q | First examination report despatched |
Effective date: 20090202 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090613 |